ATXN3 gene
ataxin 3

Normal Function
The ATXN3 gene provides instructions for making an enzyme called ataxin-3, which is found in cells throughout the body. Ataxin-3 is involved in a mechanism called the ubiquitin-proteasome system that destroys and gets rid of excess or damaged proteins. The molecule ubiquitin attaches (binds) to unneeded proteins and tags them to be broken down (degraded) within cells. Ataxin-3 removes (cleaves) the ubiquitin from these unwanted proteins just before they are degraded so that the ubiquitin can be used again. Due to its role in cleaving ubiquitin from proteins, ataxin-3 is known as a deubiquitinating enzyme.

Researchers believe that ataxin-3 also may be involved in regulating the first stage of protein production (transcription).

Health Conditions Related to Genetic Changes
Spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3 (SCA3) is a condition characterized by progressive problems with movement. SCA3 results from a mutation in the ATXN3 gene known as a trinucleotide repeat expansion. This mutation increases the length of the repeated CAG segment in the ATXN3 gene. People with SCA3 have more than 50 CAG repeats.

The expanded CAG segment leads to the production of an abnormally long version of the ataxin-3 protein that folds into the wrong 3-dimensional shape. This nonfunctional ataxin-3 protein cannot remove ubiquitin from proteins that are no longer needed. As a result, these unwanted proteins, along with ubiquitin and ataxin-3, cluster together to form clumps (aggregates) within the nucleus of the cells. It is unclear how these aggregates affect cell function, because they are found in healthy cells as well as those that die.

Nerve cells (neurons) and other types of brain cells are most affected by mutations in the ATXN3 gene. SCA3 is associated with cell death in the part of the brain that is connected to the spinal cord (the brainstem), the part of the brain involved in coordinating movements (the cerebellum), and other areas of the brain. This condition is also associated with the death of neurons in the spinal cord. Over time, the loss of cells in the brain and spinal cord cells cause the signs and symptoms characteristic of SCA3.
**Chromosomal Location**

Cytogenetic Location: 14q32.12, which is the long (q) arm of chromosome 14 at position 32.12

Molecular Location: base pairs 92,058,552 to 92,106,621 on chromosome 14 (Homo sapiens Annotation Release 109, GRCh38.p12) (NCBI)

Credit: Genome Decoration Page/NCBI

**Other Names for This Gene**

- AT3
- ataxin-3
- ATX3
- ATX3_HUMAN

**Additional Information & Resources**

**Educational Resources**

- Basic Neurochemistry (sixth edition, 1999): Trinucleotide expansion is one of the most important categories of mutation underlying neurodegenerative disorders
  https://www.ncbi.nlm.nih.gov/books/NBK27942/#A2851

- Madame Curie Bioscience Database: Ubiquitination/De-Ubiquitination
  https://www.ncbi.nlm.nih.gov/books/NBK6166/#A65133

- Washington University, St. Louis: Neuromuscular Disease Center
  https://neuromuscular.wustl.edu/ataxia/domatax.html#mjd

**Clinical Information from GeneReviews**

- Spinocerebellar Ataxia Type 3
  https://www.ncbi.nlm.nih.gov/books/NBK1196
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28ATXN3%5BTIAB%5D%29+OR+%28ataxin+3%5BTIAB%5D%29%29+AND+%28%28Genes%5BMH%5D%29%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- ATAXIN 3
  http://omim.org/entry/607047

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/GC_ATXN3.html
- ClinVar
  https://www.ncbi.nlm.nih.gov/clinvar?term=ATXN3%5Bgene%5D
- HGNC Gene Symbol Report
- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:4287
- NCBI Gene
- UniProt
  https://www.uniprot.org/uniprot/P54252

Sources for This Summary

- OMIM: ATAXIN 3
  http://omim.org/entry/607047
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818316/